https://www.selleckchem.com/products/ABT-888.html
The current study aimed to assess the impact of HIV on the production of anti-HCV antibodies in HCV-infected individuals with advanced HCV-related cirrhosis before and 36 weeks after the sustained virological response (SVR) induced by direct-acting antivirals (DAAs) therapy. Prospective study on 62 patients (50 HIV/HCV-coinfected and 12 HCV-monoinfected). Plasma anti-E2 and HCV-nAbs were determined respectively by ELISA and microneutralization assays. At baseline, the HCV-group had higher anti-E2 levels against Gt1a (p=0.012), Gt1b (p=0
Curtir
Comentario
Compartilhar
